A new trading day began on Tuesday, with Y-Mabs Therapeutics Inc (NASDAQ: YMAB) stock price down -6.18% from the previous day of trading, before settling in for the closing price of $6.15. YMAB’s price has ranged from $5.71 to $20.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 46.29%. Meanwhile, its annual earnings per share averaged -25.64%. With a float of $36.97 million, this company’s outstanding shares have now reached $44.77 million.
Let’s determine the extent of company efficiency that accounts for 100 employees. In terms of profitability, gross margin is 88.83%, operating margin of -33.66%, and the pretax margin is -27.28%.
Y-Mabs Therapeutics Inc (YMAB) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Y-Mabs Therapeutics Inc is 17.46%, while institutional ownership is 60.07%. The most recent insider transaction that took place on Sep 13 ’24, was worth 875,550. In this transaction CHIEF BUSINESS OFFICER of this company sold 65,000 shares at a rate of $13.47, taking the stock ownership to the 97,681 shares. Before that another transaction happened on Sep 16 ’24, when Company’s CHIEF BUSINESS OFFICER sold 30,000 for $12.97, making the entire transaction worth $389,100. This insider now owns 67,681 shares in total.
Y-Mabs Therapeutics Inc (YMAB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.81% during the next five years compared to 20.06% growth over the previous five years of trading.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Here are Y-Mabs Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Looking closely at Y-Mabs Therapeutics Inc (NASDAQ: YMAB), its last 5-days average volume was 0.58 million, which is a jump from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 42.98%. Additionally, its Average True Range was 0.42.
During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 1.15%, which indicates a significant decrease from 10.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.04% in the past 14 days, which was lower than the 55.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.90, while its 200-day Moving Average is $11.75. However, in the short run, Y-Mabs Therapeutics Inc’s stock first resistance to watch stands at $6.10. Second resistance stands at $6.44. The third major resistance level sits at $6.66. If the price goes on to break the first support level at $5.54, it is likely to go to the next support level at $5.32. Now, if the price goes above the second support level, the third support stands at $4.98.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats
With a market capitalization of 258.43 million, the company has a total of 44,789K Shares Outstanding. Currently, annual sales are 84,820 K while annual income is -21,430 K. The company’s previous quarter sales were 18,460 K while its latest quarter income was -7,000 K.
